Use of antagonists of plasminogen activator inhibitor-1 (PAI-1) for the treatment of asthma and chronic obstructive pulmonary disease
US6767540B2 · kind B2 · utility
2Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 12, 2001 |
| Grant date | Jul 27, 2004 |
| Priority date | — |
| Expiry date | Jan 12, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods for treatment of asthma and chronic obstructive pulmonary disease (COPD) by administration of antagonists to plasminogen activator inhibitor type-1 (PAI-1). Suitable atagonists include antibodies, peptides, proteins, nucleic acids, small organic molecules and polymers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.